Abstract:Cisplatin chemoresistance is a clinical obstacle in the treatment of gastric cancer (GC). Enhanced DNA repair capacity may lead to cisplatin resistance. However, the detailed molecular mechanism of GC cisplatin resistance specifically involving nucleotide excision repair (NER) is not clear. However, the mechanism through which the NER pathway contributes to cisplatin resistance in GC is still unclear. In light of the crucial role of microRNAs (miRNAs) in regulating protein expression and biological behavior, we aimed to analyze the expression and function of miR-192-5p in the NER pathway and its role in cisplatin resistance in GC. Comet assays were performed to measure the amount of DNA damage and repair in the SGC7901 and SGC7901/DDP GC cell lines by observing the tail length. MiRNA expression levels in SGC7901/DDP and SGC7901 cells were detected by microarray. Quantitative real-time PCR (qRT-PCR) was carried out to confirm the expression level of miR-192-5p. Lentiviral vector transfection modifies miR-192-5p levels in SGC7901/DDP and SGC7901 cells. The IC50 values of cisplatin-treated cells were assessed by MTT assays. The protein level was determined by Western blot and immunohistochemistry. With enhanced DNA repair, the expression levels of ERC3 and ERC4 in SGC 7901 DDP cells increased, while miR-1'92-5p was significantly downregulated in SGC7901/DDP compared with SGC7901 cells. ERCC3 and ERCC4 were identified as the main targets of miR-192-5p. Forced expression of miR-192-5p in SGC7901/DDP cells significantly inhibited the expression of ERCC3 and ERCC4, making GC cells more sensitive to cisplatin in vitro and in vivo. In contrast, knockdown of miR-192-5p expression in SGC7901 cells increased the expression of ERCC3 and ERCC4, resulting in cisplatin resistance in vitro and in vivo. MiR-192-5p partially reversed GC cisplatin resistance by targeting ERCC3 and ERCC4, which participate in the NER pathway, suggesting that miR-192-5p may be a potential biomarker and therapeutic target for GC cisplatin resistance.

Microrna-302a Sensitizes Testicular Embryonal Carcinoma Cells to Cisplatin-Induced Cell Death

MicroRNA-191 Modulates Cisplatin-Induced DNA Damage Response by Targeting RCC2.

Targeted Inhibition of miR-221/222 Promotes Cell Sensitivity to Cisplatin in Triple-Negative Breast Cancer MDA-MB-231 Cells.

Mir-503 Regulates the Resistance of Non-Small Cell Lung Cancer Cells to Cisplatin by Targeting Bcl-2.

MiR-302b as a Combinatorial Therapeutic Approach to Improve Cisplatin Chemotherapy Efficacy in Human Triple-Negative Breast Cancer

TP53TG1 enhances cisplatin sensitivity of non-small cell lung cancer cells through regulating miR-18a/PTEN axis

MicroRNA-98 Sensitizes Cisplatin-Resistant Human Lung Adenocarcinoma Cells by Up-Regulation of HMGA2.

The role of microRNA in cisplatin resistance or sensitivity

Upregulation of Microrna-181A-5p Increases the Sensitivity of HS578T Breast Cancer Cells to Cisplatin by Inducing Vitamin D Receptor-Mediated Cell Autophagy

Upregulation of Microrna-451 Increases Cisplatin Sensitivity of Non-Small Cell Lung Cancer Cell Line (A549)

Microrna-30a Sensitizes Tumor Cells to Cis-Platinum Via Suppressing Beclin 1-Mediated Autophagy

MiR-192-5p reverses cisplatin resistance by targeting ERCC3 and ERCC4 in SGC7901/DDP cells.

Mir-340 Reverses Cisplatin Resistance Of Hepatocellular Carcinoma Cell Lines By Targeting Nrf2-Dependent Antioxidant Pathway

Downregulation of Microrna-196A Enhances the Sensitivity of Non-Small Cell Lung Cancer Cells to Cisplatin Treatment

MicroRNAs as Regulators of Cisplatin Resistance in Lung Cancer.

Mir-509-3p Promotes Cisplatin-Induced Apoptosis in Ovarian Cancer Cells Through the Regulation of Anti-Apoptotic Genes.

Phospho-ΔNp63α/miR-885-3p axis in tumor cell life and cell death upon cisplatin exposure.

The Role of miRNAs in Cisplatin-Resistant HeLa Cells.

Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy

MicroRNA-181a Enhances the Chemoresistance of Human Cervical Squamous Cell Carcinoma to Cisplatin by Targeting PRKCD.

MiR-302a-3p reduces cisplatin resistance of esophageal squamous cell carcinoma cells by targeting EphA2